4 unknown, 2 completed, 1 recruiting. 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 2, Completed 1, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Cytotoxins: new trials by email Literature Review of Cytotoxins trials Research Report on Cytotoxins
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial Antiandrogen Therapy, Bone Scan, Computed Tomography - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2024-02-18 | 2026-10-08 |
| A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer cytotoxic chemotherapy (docetaxel or epirubicin or cyclophosphamide or carboplatin), anti-Her2 monoclonal antibody (Trastuzumab, Pertuzumab), traditional herbal medicine - Stage II-III Breast Cancer | Phase 2 | Unknown | Shengjing Hospital | 100 | 2021-10-20 | 2022-08-05 |
| A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment SNK01 (Super Natural Killer Cells 01), GC, Cetuximab - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | NKMAX Co., Ltd. | 24 | 2021-07-08 | 2021-07-21 |
| Use of Immunosuppressive Therapy for Sarcoidosis Cytotoxic drug - Sarcoidosis | Unknown | University of Cincinnati | 2000 | 2014-11-01 | 2017-08-14 | |
| Combine TACE and RFA Versus TACE Alone for HCC With PVTT TACE, RFA, pirarubicin,mitomycin and lobaplatin - Hepatocellular Carcinoma | Phase 3 | Unknown | Ming Zhao | 240 | 2014-10-01 | 2016-04-14 |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer BIIB022 With Paclitaxel and Carboplatin - Non-Small Cell Lung Cancer | Phase 1 | Completed | Biogen | 18 | 2009-10-01 | 2013-09-16 |
| Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma Taxane (Cytotoxic, BAY59-8862) - Lymphoma, Non-Hodgkin | Phase 2 | Completed | Bayer | 29 | 2002-02-01 | 2013-10-14 |
Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Prostatic Neoplasms (1) · Sarcoidosis (1)
Bayer (1) · Biogen (1) · Ming Zhao (1) · NKMAX Co., Ltd. (1) · Northwestern University (1) · Shengjing Hospital (1) · University of Cincinnati (1)
United States (4) · China (2) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · South Korea (1) · United Kingdom (1)
Caigang Liu, doctor (1) · David VanderWeele, MD, PhD (1) · Ming Zhao, doctor (1) · Robert P Baughman, MD (1)
PMID 27614001, PMID 34255140, PMID 38538093
P30CA060553 (1)